FokkeC.van den BergBDrenthenJWalgaardCvan DoornPAJacobsBC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33-43.
3.
KinboshiM.InoueMKojimaY, et al.Pain in the acute phase of Guillain–Barre syndrome. Neurol Clin Neurosci. 2014;2(2):50-53.
4.
KaboreR.MagyLBoukhrisSMabroukTLacosteMVallatJM. Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome. Rev Neurol. 2004;160(8-9):821-823.
5.
JinP.H.ShinS.C.DhamoonM.S.Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: A case-crossover study. Muscle Nerve. 2020;62(3):327-332.
6.
NicholsonM.GoubranHChanNSiegalD. No apparent association between mRNA COVID-19 vaccination and venous thromboembolism. Blood Rev. 2022;56:100970.
7.
HansonK.E.GoddardKLewisN, et al.Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink. JAMA Network Open. 2022;5(4):e228879-e228879.
